India vs Luxembourg: Pneumococcal conjugate second or third-dose vaccines (PCVc)
India
97.0%
in 2025
Luxembourg
97.0%
in 2025
India rank
16th
Luxembourg rank
16th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- India
- Luxembourg
How they compare
India currently reports 97.0% against 97.0% in Luxembourg, a difference of 0.0%.
Across all 18 years both countries report, Luxembourg has been ahead every year.
India ranks 16th and Luxembourg ranks 16th of 192 countries.
Luxembourg has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | India | Luxembourg | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 86.0% | 86.0% | Luxembourg |
| 2010s | 2.1% | 93.4% | 91.3% | Luxembourg |
| 2020s | 64.5% | 96.7% | 32.2% | Luxembourg |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), India or Luxembourg?
- India, at 97.0% against 97.0% in Luxembourg as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between India and Luxembourg?
- 0.0%, with India ahead.
- How many years of comparable data are there for India and Luxembourg?
- 18 years are reported by both, from 2008 to 2025.
- How do India and Luxembourg rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- India ranks 16th and Luxembourg ranks 16th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.